Deng-Yuan Liou, MD
Neurology · San Diego, CANPI 1932668084
Payments from drug & device makers
What this record shows
This record is dominated by grants: $12,000 of the $14,670 with a category attached, or 81.8%. 14 manufacturers reported payments, led by Medtronic at 51.7% of the total. Reporting peaked in 2023 at $12,044 and has fallen 98.0% since, to $246 in 2025.
Across 45 payments — averaging $326.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Abbott$6K
- Neurocrine Biosciences, Inc.$221
- Sanofi$148
- Biogen$122
- Boston Scientific$108
- plus $356 from 8 others
What the payments were for
- Grants$12,00082%
- Travel & lodging$1,2799%
- Food & beverage$1,3069%
- Education$851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 2 | $7,585 |
| Abbott | 10 | $6,130 |
| Neurocrine Biosciences, Inc. | 3 | $221 |
| Sanofi | 8 | $148 |
| Biogen | 1 | $122 |
| Boston Scientific | 3 | $108 |
| AstraZeneca(2 entities) | 6 | $88 |
| Merz Pharmaceuticals, LLC | 1 | $85 |
| CSL Behring | 4 | $73 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Averitas Pharma Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $17 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,670 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 12 | $25,822 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 12 | $1,556 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 34 | $1,194 |
| Gabapentin | 15 | $300 |
| Donepezil Hcl | 11 | $166 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Diego
- Chamindra LavertySan Diego$662K
- Hossein AnsariSan Diego$377K
- Revere KinkelSan Diego$266K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.